Here's why the Immutep (ASX:IMM) share price is climbing today

The Immutep Ltd (ASX: IMM) share price is climbing in late-morning trade after announcing a new European patent grant. Here's all the details.

The Immutep Ltd (ASX: IMM) share price is climbing in late-morning trade after announcing a new European patent grant. At the time of writing, the biotechnology company's shares are swapping hands for 44 cents, up 2.35%.

What was announced?

Investors are pushing Immutep shares higher after digesting the company's positive update.

According to its release, Immutep advised that it has been granted a patent to add to its portfolio. Approved by the European Patent Office, the latest addition will seek to further protecting Immutep's intellectual property.

The new patent is titled, 'Combination therapies comprising antibody molecules to LAG-3' (patent number EP3317301).

Immutep stated that the patent discusses LAG525, a humanised form of its IMP701 antibody. This is out-licensed to Novartis AG. The new patent also explains how to use LAG525 and spartalizumab. This is an anti-PD-1 antibody molecule that can be used to treat cancer patients.

Developed by Immutep, IMP701 is a therapeutic antibody previously used to target LAG-3. The antibody works in controlling the signalling pathways, activating T cell function. Thus, it removes two brakes to allow the immune system to kill cancer cells.

Immutep noted that rights to the development and commercialisation of IMP701 are exclusively licensed to Novartis. Currently, LAG525 is being evaluated in several trials by Novartis in combination with its PD-1 inhibitor spartalizumab. In addition, Immutep is eligible to receive development-based milestone payments and sales-based royalties on achieving its agreed targets.

The EP3317301 patent is also jointly owned by Novartis and Immutep, and is set to expire on 28 July 2036.

Immutep share price review

In the past 12 months, the Immutep share price has gained 250%, with most of those gains coming in 2020. Year-to-date, the company's shares are up just 5% after recording heavy selling during March.

On valuation grounds, Immutep has a market capitalisation of roughly $292.4 million, with 672.3 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Man working on a laptop from home.
ASX Share Market News

5 things to watch on the ASX 200 on Wednesday

It could be another tough session for Aussie investors on hump day.

Read more »

A woman sprints with a trail of fire blazing from her body.
Opinions

I hunted the ASX for shares with the potential to double. This one stood out

Do you have this ASX share in your investment portfolio?

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Opinions

I wanted growth, not hype. Only 3 ASX shares passed my checks

One of these ASX shares is tipped to climb up to 38%.

Read more »

Army man holding a drone while the army woman holds the remote control.
52-Week Lows

Can DroneShield shares rebound from fresh 52-week low, or is there more downside ahead?

Investors have fallen out of love with the counter-drone operator’s shares.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Buy, hold, sell: Fortescue, Santos, CBA shares

Let's review some new expert ratings and insights on 3 ASX 200 heavyweights.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »

Frustrated man looking exhausted while sitting at his desk with his laptop and carrying his glasses in his hand.
ASX Share Market News

5 things to watch on the ASX 200 on Tuesday

It looks set to be a tough session for Aussie investors.

Read more »